Scientific Advisory Board Member
Candace S. Johnson, Ph.D. is Deputy Director Roswell Park Cancer Institute and Chair, Department of Pharmacology & Therapeutics, Wallace Chair in Translational Research and Professor of Pharmaceutical Sciences at the University of Buffalo. She joined the faculty of Roswell Park Cancer Institute in February 2002, after serving as the Deputy Director of Basic Research at the University of Pittsburgh Cancer Institute, and Professor of Pharmacology and Medicine at the University of Pittsburgh School of Medicine. Dr. Johnson earned her doctoral degree in Immunology from Ohio State University, Columbus, in 1977. From 1977 to 1981, she completed research and postdoctoral fellowships in Immunology/Cell Biology at the Michigan Cancer Foundation, Detroit.
Dr. Johnson’s research interests include translational research to facilitate the efficient application of promising laboratory findings in clinical studies; preclinical design and development of more effective therapeutic approaches to cancer using highly characterized tumor models; and mechanisms of vitamin D mediated antiproliferative effects either alone or in combination with other cytotoxic agents. Dr. Johnson is a member of the National Institutes of Health Reviewers Reserve and has served as a member of the National Cancer Institute Review Group Subcommittee A Cancer Center (Parent Committee) and of the Experimental Therapeutics Study Section (2) for 2 terms. She also is a member of many professional and scientific societies, Associate Editor of Molecular and Cellular Differentiation, Oncology, and Molecular Pharmacology, and member of the editorial board of Oncology Reports, Molecular Cancer Therapeutics and Molecular Pharmacology. Dr. Johnson has authored or coauthored more than 130 journal publications, book chapters and abstracts, and has been issued patents on the “Use of Pretreatment Chemicals to Enhance Efficacy of Cytotoxic Agents” and “Endothelial Specific Targeting.”